10.1002/oby.21042 58
Will it help with brain fog, cognitive decline, or dementia
Co-occurring symptom clusters emerged, with Cluster 1 encompassing a mix of somatic and psychological symptoms (such as allergies, anxiety, and hypertension), Cluster 2 encompassing neuromuscular and metabolic symptoms (such as dehydration, headache, and hypoglycemia), and Cluster 3 focusing on gastrointestinal distress
One section of the Federal Food, Drug, and Cosmetic Act allows compounding if the drug is changed in a way that makes a significant difference for the patient compared with the commercially available drug
Alcohol consumption may interfere with glycemic control and can exacerbate gastrointestinal side effects
In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]